Integrum establishes Center of Excellence in Ukraine
Mölndal, Sweden – December 20, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.
The need for amputee care in Ukraine has increased rapidly since the Russian invasion. More than 20,000 individuals have lost extremities, which has put a high strain on the healthcare system and created a significant need for swift actions on an infrastructure level. The new Center of Excellence is operational following recent visits to Ukraine by Dr. Brånemark. Two senior surgeons have already been trained and certified to perform both transfemoral and transhumeral surgeries using Integrum’s innovative OPRA™ Implant System.
More than 10 patients have already been treated using Integrum's implant system. This was initially done as a pro bono initiative by Dr. Brånemark and Integrum but is now also part of Integrum’s commercial operations.
“Following our recent efforts in Ukraine, we have had constructive conversations with resourceful partners working tirelessly to restore war victims' health. We are proud to take part in the establishment of the Center of Excellence in Kyiv, which will function both as a medical center for the clinical care of patients who have suffered limb loss and as a beacon of knowledge for surgeons to learn how to perform reconstructive surgery using the OPRA™ Implant System," says Rickard Brånemark, CEO of Integrum.
For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.